1. Home
  2. KROS vs LEGH Comparison

KROS vs LEGH Comparison

Compare KROS & LEGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • LEGH
  • Stock Information
  • Founded
  • KROS 2015
  • LEGH 2005
  • Country
  • KROS United States
  • LEGH United States
  • Employees
  • KROS N/A
  • LEGH N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • LEGH Homebuilding
  • Sector
  • KROS Health Care
  • LEGH Consumer Discretionary
  • Exchange
  • KROS Nasdaq
  • LEGH Nasdaq
  • Market Cap
  • KROS 558.9M
  • LEGH 588.8M
  • IPO Year
  • KROS 2020
  • LEGH 2018
  • Fundamental
  • Price
  • KROS $13.41
  • LEGH $23.91
  • Analyst Decision
  • KROS Buy
  • LEGH Strong Buy
  • Analyst Count
  • KROS 13
  • LEGH 2
  • Target Price
  • KROS $20.63
  • LEGH $29.00
  • AVG Volume (30 Days)
  • KROS 606.6K
  • LEGH 103.5K
  • Earning Date
  • KROS 08-06-2025
  • LEGH 08-07-2025
  • Dividend Yield
  • KROS N/A
  • LEGH N/A
  • EPS Growth
  • KROS N/A
  • LEGH 8.04
  • EPS
  • KROS 0.11
  • LEGH 2.29
  • Revenue
  • KROS $214,713,000.00
  • LEGH $176,618,000.00
  • Revenue This Year
  • KROS $5,006.76
  • LEGH N/A
  • Revenue Next Year
  • KROS N/A
  • LEGH $8.23
  • P/E Ratio
  • KROS $122.43
  • LEGH $10.43
  • Revenue Growth
  • KROS 91657.70
  • LEGH N/A
  • 52 Week Low
  • KROS $9.12
  • LEGH $21.58
  • 52 Week High
  • KROS $72.37
  • LEGH $29.31
  • Technical
  • Relative Strength Index (RSI)
  • KROS 42.34
  • LEGH 63.30
  • Support Level
  • KROS $13.25
  • LEGH $21.91
  • Resistance Level
  • KROS $13.99
  • LEGH $24.17
  • Average True Range (ATR)
  • KROS 0.39
  • LEGH 0.65
  • MACD
  • KROS -0.06
  • LEGH 0.25
  • Stochastic Oscillator
  • KROS 22.49
  • LEGH 89.96

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About LEGH Legacy Housing Corporation (TX)

Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.

Share on Social Networks: